O	0	1	A
O	2	12	randomized
O	12	13	,
O	14	20	double
O	20	21	-
O	21	26	blind
O	26	27	,
O	28	33	phase
O	34	35	2
O	36	41	study
O	42	44	of
B-intervention	45	56	ruxolitinib
O	57	59	or
B-control	60	67	placebo
I-control	68	70	in
I-control	71	82	combination
I-control	83	87	with
I-control	88	100	capecitabine
O	101	103	in
O	104	112	patients
O	113	117	with
O	118	126	advanced
O	127	131	HER2
O	131	132	-
O	132	140	negative
O	141	147	breast
O	148	154	cancer
O	155	158	and
O	159	167	elevated
O	168	169	C
O	169	170	-
O	170	178	reactive
O	179	186	protein
O	186	187	,
O	188	189	a
O	190	196	marker
O	197	199	of
O	200	208	systemic
O	209	221	inflammation
O	221	222	.

O	223	226	The
O	227	232	Janus
O	232	233	-
O	233	243	associated
O	244	250	kinase
O	251	252	(
O	252	255	JAK
O	255	256	)
O	256	257	/
O	257	263	signal
O	264	274	transducer
O	275	278	and
O	279	288	activator
O	289	291	of
O	292	305	transcription
O	306	313	pathway
O	314	316	is
O	317	318	a
O	319	322	key
O	323	332	regulator
O	333	335	of
O	336	348	inflammatory
O	349	358	signaling
O	358	359	,
O	360	370	associated
O	371	375	with
O	376	389	tumorigenesis
O	389	390	,
O	391	395	cell
O	396	404	survival
O	404	405	,
O	406	409	and
O	410	421	progression
O	421	422	.

O	423	427	This
O	428	438	randomized
O	439	444	phase
O	445	446	2
O	447	452	trial
O	453	462	evaluated
O	463	466	the
O	467	475	efficacy
O	476	479	and
O	480	486	safety
O	487	489	of
O	490	493	the
O	494	502	addition
O	503	505	of
O	506	517	ruxolitinib
O	517	518	,
O	519	520	a
O	521	525	JAK1
O	525	526	/
O	526	530	JAK2
O	531	540	inhibitor
O	540	541	,
O	542	544	to
O	545	557	capecitabine
O	558	560	in
O	561	569	patients
O	570	574	with
O	575	579	HER2
O	579	580	-
O	580	588	negative
O	589	597	advanced
O	598	604	breast
O	605	611	cancer
O	612	615	and
O	616	620	high
O	621	629	systemic
O	630	642	inflammation
O	643	644	(
O	644	652	modified
O	653	660	Glasgow
O	661	671	Prognostic
O	672	677	Score
O	678	679	[
O	679	683	mGPS
O	683	684	]
O	685	686	≥
O	687	688	1
O	688	689	)
O	689	690	.

B-eligibility	691	699	Patients
I-eligibility	700	704	with
I-eligibility	705	706	≤
I-eligibility	707	708	2
I-eligibility	709	714	prior
I-eligibility	715	727	chemotherapy
I-eligibility	728	736	regimens
I-eligibility	737	740	for
I-eligibility	741	749	advanced
I-eligibility	750	752	or
I-eligibility	753	763	metastatic
I-eligibility	764	771	disease
I-eligibility	772	774	or
I-eligibility	775	782	hormone
I-eligibility	783	791	receptor
I-eligibility	791	792	-
I-eligibility	792	800	positive
I-eligibility	801	809	patients
I-eligibility	810	814	with
I-eligibility	815	822	disease
I-eligibility	823	834	progression
I-eligibility	835	837	on
I-eligibility	838	843	prior
I-eligibility	844	852	hormonal
I-eligibility	853	862	therapies
O	863	867	were
O	868	878	randomized
O	879	880	1
O	880	881	:
O	881	882	1
O	883	885	to
O	886	888	21
O	888	889	-
O	889	892	day
O	893	899	cycles
O	900	902	of
O	903	914	ruxolitinib
O	915	916	(
O	916	917	n
O	918	919	=
B-intervention-participants	920	922	76
O	922	923	)
O	924	926	or
O	927	934	placebo
O	935	936	(
O	936	937	n
O	938	939	=
B-control-participants	940	942	73
O	942	943	)
O	944	948	plus
O	949	961	capecitabine
O	961	962	.

O	963	966	The
O	967	974	primary
O	975	983	endpoint
O	984	987	was
B-outcome-Measure	988	995	overall
I-outcome-Measure	996	1004	survival
I-outcome-Measure	1005	1006	(
I-outcome-Measure	1006	1008	OS
I-outcome-Measure	1008	1009	)
O	1009	1010	.

O	1011	1019	Baseline
O	1020	1035	characteristics
O	1036	1040	were
O	1041	1045	well
O	1046	1054	balanced
O	1055	1062	between
O	1063	1069	groups
O	1069	1070	.

O	1071	1074	For
B-intervention	1075	1086	ruxolitinib
I-intervention	1087	1091	plus
I-intervention	1092	1104	capecitabine
O	1105	1111	versus
B-control	1112	1119	placebo
I-control	1120	1124	plus
I-control	1125	1137	capecitabine
O	1137	1138	,
B-outcome	1139	1145	median
I-outcome	1146	1148	OS
O	1149	1152	was
B-iv-cont-median	1153	1155	11
I-iv-cont-median	1155	1156	.
I-iv-cont-median	1156	1157	2
I-iv-cont-median	1158	1164	months
O	1165	1171	versus
B-cv-cont-median	1172	1174	10
I-cv-cont-median	1174	1175	.
I-cv-cont-median	1175	1176	9
I-cv-cont-median	1177	1183	months
O	1184	1185	(
O	1185	1188	log
O	1188	1189	-
O	1189	1193	rank
O	1194	1198	test
O	1199	1200	P
O	1201	1202	=
O	1203	1204	0
O	1204	1205	.
O	1205	1208	762
O	1208	1209	)
O	1209	1210	;
B-outcome	1211	1217	median
I-outcome	1218	1229	progression
I-outcome	1229	1230	-
I-outcome	1230	1234	free
I-outcome	1235	1243	survival
I-outcome	1244	1245	(
I-outcome	1245	1248	PFS
I-outcome	1248	1249	)
O	1250	1253	was
B-iv-cont-median	1254	1255	4
I-iv-cont-median	1255	1256	.
I-iv-cont-median	1256	1257	5
I-iv-cont-median	1258	1264	months
O	1265	1271	versus
B-cv-cont-median	1272	1273	2
I-cv-cont-median	1273	1274	.
I-cv-cont-median	1274	1275	5
I-cv-cont-median	1276	1282	months
O	1283	1284	(
O	1284	1287	log
O	1287	1288	-
O	1288	1292	rank
O	1293	1297	test
O	1298	1299	P
O	1300	1301	=
O	1302	1303	0
O	1303	1304	.
O	1304	1307	151
O	1307	1308	)
O	1308	1309	;
O	1310	1313	and
B-outcome	1314	1321	overall
I-outcome	1322	1330	response
I-outcome	1331	1335	rate
I-outcome	1336	1337	(
I-outcome	1337	1340	ORR
I-outcome	1340	1341	)
O	1342	1345	was
B-iv-bin-percent	1346	1348	28
I-iv-bin-percent	1348	1349	.
I-iv-bin-percent	1349	1350	9
I-iv-bin-percent	1350	1351	%
O	1352	1358	versus
B-cv-bin-percent	1359	1361	13
I-cv-bin-percent	1361	1362	.
I-cv-bin-percent	1362	1363	7
I-cv-bin-percent	1363	1364	%
O	1365	1366	(
O	1366	1373	Cochran
O	1373	1374	-
O	1374	1380	Mantel
O	1380	1381	-
O	1381	1389	Haenszel
O	1390	1394	test
O	1395	1396	P
O	1397	1398	=
O	1399	1400	0
O	1400	1401	.
O	1401	1404	024
O	1404	1405	)
O	1405	1406	,
O	1407	1419	respectively
O	1419	1420	.

O	1421	1422	A
O	1423	1427	more
O	1428	1437	favorable
O	1438	1444	change
O	1445	1447	in
B-outcome	1448	1454	health
I-outcome	1454	1455	-
I-outcome	1455	1462	related
I-outcome	1463	1470	quality
I-outcome	1471	1473	of
I-outcome	1474	1478	life
O	1479	1480	(
O	1480	1485	HRQoL
O	1485	1486	)
O	1487	1490	was
O	1491	1499	observed
O	1500	1504	with
O	1505	1516	ruxolitinib
O	1517	1521	plus
O	1522	1534	capecitabine
O	1535	1541	versus
O	1542	1549	placebo
O	1550	1554	plus
O	1555	1567	capecitabine
O	1567	1568	.

O	1569	1573	Both
O	1574	1582	regimens
O	1583	1587	were
O	1588	1597	generally
O	1598	1607	tolerable
O	1607	1608	.

O	1609	1610	A
O	1611	1617	higher
B-outcome	1618	1627	incidence
I-outcome	1628	1630	of
I-outcome	1631	1636	grade
I-outcome	1637	1638	3
I-outcome	1638	1639	/
I-outcome	1639	1640	4
I-outcome	1641	1647	anemia
O	1648	1649	(
B-iv-bin-percent	1649	1651	25
I-iv-bin-percent	1651	1652	.
I-iv-bin-percent	1652	1653	4
I-iv-bin-percent	1653	1654	%
O	1655	1657	vs
B-cv-bin-percent	1658	1659	5
I-cv-bin-percent	1659	1660	.
I-cv-bin-percent	1660	1661	6
I-cv-bin-percent	1661	1662	%
O	1662	1663	)
O	1664	1667	and
O	1668	1669	a
O	1670	1675	lower
B-outcome	1676	1685	incidence
I-outcome	1686	1688	of
I-outcome	1689	1694	grade
I-outcome	1695	1696	3
I-outcome	1696	1697	/
I-outcome	1697	1698	4
I-outcome	1699	1705	palmar
I-outcome	1705	1706	-
I-outcome	1706	1713	plantar
I-outcome	1714	1732	erythrodysesthesia
O	1733	1734	(
B-iv-bin-percent	1734	1735	1
I-iv-bin-percent	1735	1736	.
I-iv-bin-percent	1736	1737	4
I-iv-bin-percent	1737	1738	%
O	1739	1741	vs
B-cv-bin-percent	1742	1744	12
I-cv-bin-percent	1744	1745	.
I-cv-bin-percent	1745	1746	7
I-cv-bin-percent	1746	1747	%
O	1747	1748	)
O	1749	1757	occurred
O	1758	1762	with
O	1763	1774	ruxolitinib
O	1775	1779	plus
O	1780	1792	capecitabine
O	1793	1799	versus
O	1800	1807	placebo
O	1808	1812	plus
O	1813	1825	capecitabine
O	1825	1826	.

O	1827	1830	The
O	1831	1839	addition
O	1840	1842	of
O	1843	1854	ruxolitinib
O	1855	1857	to
O	1858	1870	capecitabine
O	1871	1874	for
O	1875	1883	patients
O	1884	1888	with
O	1889	1897	advanced
O	1898	1904	breast
O	1905	1911	cancer
O	1912	1915	and
O	1916	1920	high
O	1921	1929	systemic
O	1930	1942	inflammation
O	1943	1946	was
O	1947	1956	generally
O	1957	1966	tolerable
O	1966	1967	;
O	1968	1971	ORR
O	1972	1975	was
O	1976	1987	numerically
O	1988	1995	greater
O	1995	1996	,
O	1997	1998	a
O	1999	2003	more
O	2004	2013	favorable
O	2014	2020	change
O	2021	2023	in
O	2024	2029	HRQoL
O	2030	2033	was
O	2034	2042	observed
O	2042	2043	,
O	2044	2047	but
O	2048	2055	neither
O	2056	2058	OS
O	2059	2062	nor
O	2063	2066	PFS
O	2067	2070	was
O	2071	2079	improved
O	2080	2088	compared
O	2089	2093	with
O	2094	2101	placebo
O	2102	2106	plus
O	2107	2119	capecitabine
O	2119	2120	.
